Probiodrug AG (Euronext Amsterdam: PBD)

https://www.probiodrug.de

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. *

	Start	1997-06-01 established_pre
	End	2019-06-11 renamed
	Group	Vivoryon (Group)
	Today	Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
	Predecessor	Probiodrug Gesellschaft für Arzneimittelforschung mbH
	Successor	Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
	Industry	drug development technology
	Industry 2	QC inhibitor (glutam(in)yl cyclase inhibitor)
	Person	Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
	Person 2	Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)

	Region	Halle (Saale)
	Country	Germany
	Street	22 Weinbergweg
	City	06120 Halle (Saale)
	Tel	+49-345-55599-00
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2016-12-31)
	Currency	EUR
	Annual sales	44,000 (operating income (2015) 2015-12-31)
	Profit	-13,891,000 (2016-12-31)
	Cash	9,300,000 (2018-03-31)

		* Document for »About Section«:

		Record changed: 2023-12-30